Cargando…
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587980/ https://www.ncbi.nlm.nih.gov/pubmed/30478940 http://dx.doi.org/10.1111/bjh.15666 |
| _version_ | 1783429178517880832 |
|---|---|
| author | Wierda, William G. Byrd, John C. Davids, Matthew S. Furman, Richard R. Cheson, Bruce D. Barr, Paul M. Eradat, Herbert Heffner, Leonard Zhou, Lang Verdugo, Maria Potluri, Jalaja Choi, Michael |
| author_facet | Wierda, William G. Byrd, John C. Davids, Matthew S. Furman, Richard R. Cheson, Bruce D. Barr, Paul M. Eradat, Herbert Heffner, Leonard Zhou, Lang Verdugo, Maria Potluri, Jalaja Choi, Michael |
| author_sort | Wierda, William G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6587980 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65879802019-07-02 Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor Wierda, William G. Byrd, John C. Davids, Matthew S. Furman, Richard R. Cheson, Bruce D. Barr, Paul M. Eradat, Herbert Heffner, Leonard Zhou, Lang Verdugo, Maria Potluri, Jalaja Choi, Michael Br J Haematol Correspondence John Wiley and Sons Inc. 2018-11-27 2019-06 /pmc/articles/PMC6587980/ /pubmed/30478940 http://dx.doi.org/10.1111/bjh.15666 Text en © 2018 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Correspondence Wierda, William G. Byrd, John C. Davids, Matthew S. Furman, Richard R. Cheson, Bruce D. Barr, Paul M. Eradat, Herbert Heffner, Leonard Zhou, Lang Verdugo, Maria Potluri, Jalaja Choi, Michael Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor |
| title | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor |
| title_full | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor |
| title_fullStr | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor |
| title_full_unstemmed | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor |
| title_short | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor |
| title_sort | venetoclax for chronic lymphocytic leukaemia patients who progress after more than one b‐cell receptor pathway inhibitor |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587980/ https://www.ncbi.nlm.nih.gov/pubmed/30478940 http://dx.doi.org/10.1111/bjh.15666 |
| work_keys_str_mv | AT wierdawilliamg venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT byrdjohnc venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT davidsmatthews venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT furmanrichardr venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT chesonbruced venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT barrpaulm venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT eradatherbert venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT heffnerleonard venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT zhoulang venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT verdugomaria venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT potlurijalaja venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor AT choimichael venetoclaxforchroniclymphocyticleukaemiapatientswhoprogressaftermorethanonebcellreceptorpathwayinhibitor |